NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positi...
13 12월 2016 - 1:44AM
Business Wire
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases,
announced that the company presented results from a preclinical
study on the company’s high affinity Natural Killer (haNK) cell
therapy program at the San Antonio Breast Cancer Symposium (SABCS)
in San Antonio, TX, which was held on December 6-10, 2016.
Previous studies have shown that patients with HER2 positive
breast cancer who have the high-affinity CD16 receptor that have
been treated with Herceptin (trastuzumab) had better clinical
outcomes versus those without the high affinity receptor. In this
study, in a mouse xenograft model of HER2 positive breast cancer,
to enhance the activity of aNK (activated natural killer) cell
therapy aNK cells were engineered to express the CD16 high affinity
Fc receptor (haNK cells). Study results reported provide further
supporting evidence that antibody-dependent cellular cytotoxicity
(ADCC) mediated cancer cell killing can be further enhanced through
the recognition of the Fc fragment of a therapeutic antibody, in
this case Herceptin, and the haNK cell’s CD16 Fc receptor.
“In over 50 patients in a broad range of cancer types,
NantKwest’s aNK cell therapy has demonstrated promising indications
of efficacy and an excellent safety record,” said Patrick
Soon-Shiong, MD, Chairman and CEO of NantKwest. “In this study,
haNK cell therapy in combination with Herceptin was highly
synergistic, resulting in tumor regression and significantly better
efficacy in comparison to either agent alone. This data,
highlighting the potential benefit of combining haNK cell therapy
with Herceptin in patients with HER2-positive breast cancer,
provides further supportive evidence and a solid foundation to fast
track this program into human clinical trials.”
Collaborating on the study were research scientists from
NantBiosciences, NantCell and NantKwest.
Presentation Summary
- High-affinity Activated Natural
Killer (haNK) Cells Augment Trastuzumab Efficacy in a Mouse Model
of HER2-positive Human Metastatic Breast Cancer
- Abstract #P2-04-1-466
- Presenter: Shahrooz Rabizadeh, PhD,
NantBiosciences Inc., Culver City, CA
- Thursday, December 8, 2016, 7:30 AM,
Room Hall 1
This poster reviews the potential synergistic use of haNK cell
therapy in combination with Herceptin (trastuzumab) in patients
with HER2-positive breast cancer.
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact, (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody, and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest's NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information, please visit
http://www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161212005857/en/
NantKwest Inc.Jen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024